Trimix Injection for Erectile Dysfunction
Trimix is a compounded intracavernosal injection (ICI) containing three vasoactive medications—alprostadil (prostaglandin E1), papaverine, and phentolamine—that is administered directly into the corpus cavernosum of the penis to produce an erection sufficient for intercourse. This is a second-line therapy for erectile dysfunction when oral PDE5 inhibitors fail or are contraindicated 1.
What Trimix Contains
Trimix combines three medications that work synergistically:
- Alprostadil (prostaglandin E1): Typically 5-45 µg/mL - the only FDA-approved agent for ICI
- Papaverine: Typically 15-30 mg/mL - a smooth muscle relaxant
- Phentolamine: Typically 0.4-5 mg/mL - an alpha-blocker
The combination is more effective than alprostadil alone, with studies showing superior penile rigidity (66% vs 60%) and higher positive response rates 2, 3.
How It Is Administered
Initial Office Visit Requirements
An in-office injection test must be performed before prescribing Trimix 1. This is a clinical principle, not optional. During this visit:
- The patient receives instruction on proper injection technique
- Initial dose titration is performed to determine the optimal dose
- Detailed counseling about adverse events is provided
- The clinician observes the patient's response and ability to self-inject
Injection Technique
The medication is injected directly into the corpus cavernosum using a fine needle (typically 27-30 gauge). The injection site should alternate between sides of the penis and vary along the shaft to prevent scarring. Onset of erection occurs within 5-15 minutes, with effects lasting 1-3 hours 3.
Dose Optimization
Start with the lowest effective dose and titrate upward based on response 3. Research demonstrates that even the smallest ingredient doses produce comparable hemodynamic effects to higher doses, but with less risk of priapism 3. The goal is achieving an erection firm enough for intercourse (≥60% rigidity) without excessive duration.
Clinical Positioning in ED Treatment
According to the most recent 2025 EAU guidelines, ICI therapy (including Trimix) is positioned as:
- Second-line therapy after PDE5 inhibitor failure 4
- An option at any stage of treatment planning 4
- Particularly useful for PDE5i nonresponders, those with contraindications to oral therapy, or patient/partner preference for non-oral treatment 1
For PDE5i nonresponders, verify proper medication use and timing before escalating to ICI 4. Education about dosing and sexual stimulation can restore PDE5i effectiveness in many cases 4.
Critical Safety Considerations
Priapism Risk
The most serious adverse event is priapism (erection >4 hours), which occurs more frequently with Trimix than with alprostadil alone 3. Patients must be counseled to:
- Seek immediate medical attention if erection persists beyond 4 hours
- Understand that priapism is a urological emergency requiring aspiration, irrigation, and potentially phenylephrine injection
- Be aware that misuse or excessive dosing significantly increases priapism risk 5, 6
Other Adverse Events
Common side effects include:
- Penile pain (less than with alprostadil alone)
- Injection site bruising or hematoma
- Penile fibrosis with prolonged use
- Rarely, systemic hypotension
Contraindications
Exercise caution in patients with:
- Bleeding disorders or anticoagulation therapy
- History of priapism
- Anatomical penile deformities
Practical Advantages
Trimix offers several advantages over single-agent alprostadil:
- Lower cost: Significantly less expensive than branded alprostadil products
- Less pain: The combination produces less injection-site discomfort than alprostadil alone 3
- Higher efficacy: Superior response rates in PDE5i nonresponders 2
- Stable formulation: When properly compounded and refrigerated, maintains stability for 60-64 days 7
Combination Therapy Enhancement
Combining Trimix with oral sildenafil 100mg produces superior hemodynamic response compared to either agent alone 8. This combination significantly increases:
- Peak systolic velocity in cavernosal arteries
- Cavernosal cGMP levels (from 1130 to 2057 fmol/mL)
- Overall erectile rigidity
This combination approach may be considered for diagnostic testing or in particularly refractory cases, though it requires careful monitoring for priapism.
Storage and Handling
Trimix must be refrigerated and has a beyond-use date of approximately 60 days when properly stored 7. Patients should be instructed on proper storage and handling to maintain medication efficacy.
Key Clinical Pitfall
The most common error is inadequate patient education before prescribing. Never prescribe Trimix without the mandatory in-office test dose, proper injection training, and explicit counseling about priapism recognition and management 1. This is a clinical principle that protects both patient safety and erectile function preservation.